Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Guillermo Reglero
 + 3328 word(s) 3328 2021-07-16 11:17:33 |
2 format correction
Peter Tang
 -18 word(s) 3310 2021-10-27 02:51:41 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Reglero, G. Precision Nutrition and Cancer Relapse. Encyclopedia. Available online: https://encyclopedia.pub/entry/15434 (accessed on 24 April 2024).
Reglero G. Precision Nutrition and Cancer Relapse. Encyclopedia. Available at: https://encyclopedia.pub/entry/15434. Accessed April 24, 2024.
Reglero, Guillermo. "Precision Nutrition and Cancer Relapse" Encyclopedia, https://encyclopedia.pub/entry/15434 (accessed April 24, 2024).
Reglero, G. (2021, October 26). Precision Nutrition and Cancer Relapse. In Encyclopedia. https://encyclopedia.pub/entry/15434
Reglero, Guillermo. "Precision Nutrition and Cancer Relapse." Encyclopedia. Web. 26 October, 2021.
Precision Nutrition and Cancer Relapse
Edit
This entry is adapted from the peer-reviewed paper 10.3390/nu11112799

Precision nutrition is an emerging science that relies on well-established factors such as genetic and epigenetic variation.  Advances in genomics, metabolomics, and proteomics are improving our understanding regarding cancer metabolic diversity, resulting in detailed classifications of tumors and raising the effectiveness of precision medicine. Likewise, the growing knowledge of interactions between nutrients and the expression of certain genes could lead to cancer therapies based on precision nutrition strategies. 

precision nutrition cancer relapse bioactive phytochemical foodstuffs lung breast prostate colon leukemia

1. Introduction

1.1. Breast, Colon, Lung, Prostate and Leukemia: The Deadliest Cancers

Lung, breast, prostate, and colon cancers have the highest overall incidence and represent 36.4% of the total diagnosis according to GLOBOCAN 2018, a report that gathers data from the International Agency for Research on Cancer of the World Health Organization [1]. Besides their high occurrence, these types of cancer add up to a mortality rate that reaches 49.2% of the diagnosed cases. In addition, blood malignancies count with a rate of 6.5%, an incidence particularly worrying as it is the highest in children and young adults.
In the last five years international scientific production related to new basic and translational discoveries on cancer has grown by 5% annually. Lung, colon, breast, prostate, and leukemia cancers account for 51% of scientific publications on cancer in this period (Web of Science, Clarivate Analytics, Philadelphia, PA, USA). Many papers address the association between gene regulation and cancer progression or metastasis, still representing the main approach in cancer research.

1.1.1. Lung Cancer

Survival is the foremost concern in lung cancer due to its progressive metastasis and resistance to therapy and, furthermore, the molecular hallmarks of its malignant properties are still insufficiently known. Recently, a 17-gene panel involving critical cellular processes such as hypoxia-mediated epithelial-mesenchymal transition (EMT) or epigenetic modifications was identified as a potential biomarker tool for prediction of metastasis and prognosis in patients affected by non-small-cell lung cancer (NSCLC) [2]. Other example of the last advances in this field is the detection of the scaffold WT1-interacting protein (WTIP) as a novel tumor suppressor down-modulated in NSCLC. Lower levels of these proteins significantly correlate with poor prognosis as a result of higher rates of cell proliferation and tumorigenesis [3]. Additionally, increasing findings in immunotherapy open expectations for the improvement of the prognosis of lung cancer patients [4].

1.1.2. Breast Cancer

Regarding breast cancer, tumor heterogeneity makes patient classification according to their risk of metastatic relapse essential in order to guide decisions in adjuvant chemotherapy. However, in the era of personalized medicine, genomics alone does not provide enough knowledge to apply precision treatments to specific tumors. Therefore, complementary multi-omic studies are emerging as the most promising approaches addressing breast cancer complexity [5]. For instance, a quantitative proteotyping approach based on sequential windowed acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) has been proposed to establish key proteins for breast tumor classification [6].

1.1.3. Prostate Cancer

The application of new technologies now allows progressing in the understanding of the molecular basis of prostate cancer pathogenesis. Microarray-based transcriptomic analyses and next generation sequencing technology are examples of powerful tools for studying gene expression and changes in gene structure at the transcript level. Recent publications described new mechanisms regarding tumor suppressors in this type of tumors [7] and new potential therapeutic targets [8]. Also, these technologies played a critical role in recent studies indicating specific gene fusions, present in at least 50% of prostate tumors, as key modulators of gene expression promoting tumor growth and progression in prostate cancer [9].

1.1.4. Colorectal Cancer

Deregulated cellular energetics is another of the hallmarks of cancer. In this sense, cooperative lipid metabolism-related genes involved in colorectal cancer progression have been recently identified. The acyl-CoA synthetase/stearoyl-CoA desaturase (ACSL/SCD) lipid network fuels migratory and invasive properties through EMT induction and is associated with an increased risk of relapse in colorectal cancer patients [10]. Other molecular mechanisms associated with the refractory nature of cancer point to cancer stem cells (CSCs). In this regard, it has been recently published that proliferation of CSC-enriched colon spheroids is dependent on mTORC1 kinase, which is activated by reactive oxygen species (ROS) produced by an NADPH oxidase [11]. Furthermore, the potential correlation between gene polymorphisms and colon cancer progression continues being studied and validated in order to identify prognostic indicators supported by mechanisms such as the increased invasiveness of tumor cells through the expression of genes involved in the activation of fatty acids through conversion to acyl-CoA [12], or the regulation of COX2 expression and cell apoptosis [13]. On the other hand, it has been recently discovered that microbiota plays an important role in colorectal carcinogenesis. This opens up new opportunities for using microbiota profiling information in colorectal cancer prevention, diagnosis, and therapy [14].

1.1.5. Blood Malignancies

Recent advances in leukemia genomics and epigenomics have facilitated the study of clonal populations and their genetic-epigenetic evolution, changing the classic view of leukemia into a complex heterogeneous disease aggravated by clonal evolution [15][16]. These findings allow a better understanding of the mechanisms involved in leukemia transformation and therapy resistance and reinforce precision medicine as the most promising approach to leukemia treatment. The complexity of this disease, together with the high number of patients showing chemotherapy resistance, evidences the urgent need of more efficient therapies. In the last years, new therapeutic approaches are being investigated, as for instance monoclonal antibodies-based treatments [17] or therapies based in macrophage targeting [18].

1.2. Cancer Relapse

Cancer relapse worsens the prognosis of patients and is a factor that contributes significantly to mortality. However, only 2% of cancer publications in the last five years deal specifically with relapse (Web of Science, using databases including MEDLINE). Cancer recurrence involves many biological interactions, such as genetic, transcription, environmental, endocrine signaling, and metabolism. These interactions add another layer of complexity in the understanding of cancer recurrence and metastasis, delaying progress in therapeutic opportunities [19]. Lung cancer and leukemia mortality rates are mainly due to their higher recurrence rates, compared to breast, colon, and prostate, for which surgical resection of the tumor combined with adjuvant treatments accomplish higher survival rates [20].
In essence, the recent discoveries in relation to drug resistance and previously unknown molecular mechanisms associated with metastasis and recurrence demand alternative therapeutic strategies, among which metabolism could emerge as a new cancer therapy support. Although cancer relapse is due to a multitude of genetic mutations and biochemical processes, advances in genomics, metabolomics, and proteomics allow better understanding of the metabolic diversity due to genetics and microbiome variation, as well as a detailed classification of tumors, which provide precision medicine with individual treatments. Likewise, the best understanding of the metabolic variation allows us to know the interactions between nutrients, metabolism, microbiota, and related genes, facilitating the development of adjuvant cancer therapies based on precision nutrition strategies [21].

1.3. Precision Nutrition and Cancer Therapy

Over the years, numerous epidemiological studies have been carried out to link the diet with cancer, either from a preventive approach or by associating the consumption of certain food products with tumor generation and growth. However, in parallel to the development of precision therapies in medicine, precision nutrition is an emerging science that relies on well-established factors such as genetic and epigenetic variation [22] and the microbiome [23]. It has recently been shown that the treatment of human cell lines with different bioactive foodstuffs influences their physiological attributes depending on their ability to influence the expression of different genes [24]. The possibility of using nutritional therapies against cancer, as a complementary medicine, is internationally accepted due to its advantages of less toxicity and better acceptance by patients [25]. In the case of breast cancer, complementary phytochemical therapy in adjuvant treatments has been proposed both with preventive effects and during conventional treatments after diagnosis [26], concluding that nutritional strategies can be effective for prevention of relapse [27].
Epidemiological studies triggered further research in terms of molecular mechanisms, which have significantly improved the effectiveness of phytotherapy, entering the context of precision nutrition [28]. Recent studies on the association between prevention, treatment, and recurrence of cancer suggest the benefit of investigating the link between specific food components and certain health outcomes [29]. Since very specific therapeutic targets must be reached, precision nutrition must be based on individual foodstuffs with well-established mechanisms of action at the molecular level in terms of gene expression modulation and signaling pathways involved in proliferation, invasion, angiogenesis, and metastasis or apoptosis [30]. For example, it has been shown that it is possible to attack genetic instability associated with cancer through nutritional strategies that inhibit proliferative signaling, attenuate oncogenic metabolism, and block inflammation [31].
The biological activity of food polyphenols, a broad family of compounds with representatives in virtually all foods, has been specially studied for decades since they have in common an intense antioxidant activity that suggests other potential health outcomes, for example in breast cancer [32]. Recently, intensive research has been carried out to determine the preventive or therapeutic activity of different natural phenolic compounds [33], opening ways for its application in new treatments of various types of cancers such as breast [34][35][36][37], colon [38], or prostate [39][40]. Some synthetic phenolic compounds have also been successfully studied for the treatment of some cancers [41]. In addition to polyphenols, curcumin (diferuloylmethane) is one of the most studied foodstuffs in recent years as a potential therapeutic product for cancer and more specifically for leukemia [42]. Traditional food products, such as rosemary extract, have been proposed as potential ingredients of precision nutritional supplements in cancer therapy, identifying molecular mechanisms related to the effects and the interactions with currently-used anticancer agents [43]. In the case of colorectal cancer, lipid-metabolism-related genes have acquired relevant interest for precision nutrition therapies, since a wide range of tumorigenic steps can be influenced by lipid metabolism, both in primary tumors and distal metastasis [44]. Certain therapeutic strategies based in diet patterns during adjuvant treatments are also sometimes considered as precision therapies [45]. Finally, multi-targeting profiles of food ingredients are being investigated regarding their potential roles triggering anti-cancer molecular mechanisms through the modulation of certain gene expressions or signaling pathways [46].

2. Current Insights on Precision Nutrition and Cancer Relapse Prevention

Since the same factors that are successfully driving precision medicine in cancer serve to design precision nutritional therapies, it is foreseeable that a new era in the treatment of cancer can be opened in coming years. Integration of nutritional strategies may be of special interest for patients treated with adjuvant therapy, in order to enhance therapy effects and to prevent cancer relapse. The knowledge regarding several bioactive foodstuffs mechanisms of action, and the fact that most of them address well established molecular targets, allows the transition into a potential clinical use. In the last decade, a growing number of research works have investigated the anticancer effects of bioactive natural products. However, only very recently have the molecular mechanisms by which nutrients may prevent relapse been explored.
Polyphenols have been the most studied family of compounds in decades for their different biological activities. In addition, some flavonoids have recently shown antitumor and antiproliferative activities that can be useful in relapse-preventive treatments. Epigallocatechin-gallate (EGCG), a flavonoid present in green tea, has been shown to inhibit tumor cell growth and increase apoptosis, promoting tumor suppression. This compound sensitizes human colon cancer cells to 5-fluorouracil, increasing the effects of adjuvant treatment and improving prognosis, and finally reducing tumor relapse risk [47]. EGCG can also prevent lung cancer relapse in lung cancer mouse xenografts by blocking the cancer stem-cells-like growth through the modulation of the hsa-mir-485-5p/RXRα axis and downregulating protein acetylation in lung carcinoma cells [48][49]. EGCG has been also been predicted to affect several pathways involved in cell death and survival, potentially leading to a reduced cancer progression [50]. However, further molecular validations are needed in this sense. Another flavonoid with interesting features for relapse prevention is quercetin, which is present in vegetables such as onions. Quercetin promotes apoptosis and inhibits cell proliferation by modulating important signaling targets as PI3K/Akt or NF-κB effectively eliminating prostate CSCs. It also limits cell migratory capacity and progression of prostate cancer cell lines by the downregulation of MK [51]. In breast cancer, quercetin can help preventing relapse by decreasing expression and activation levels of mTOR, PI3K and Akt proteins leading to a significant inhibition of MCF7 cancer cell proliferation [52]. Another flavonoid with potentially interesting effects for the development of precision nutrition products is apigenin, present in fruits, vegetables, and food herbs such as parsley. This compound improves the effectiveness of adjuvant therapy with cisplatin enhancing both cytotoxicity and its anti-migratory effect on prostate cancer stem cells [53]. Apigenin also helps preventing metastasis and relapse in non-small cell lung cancer cell lines and in an in vivo orthotopic bioluminescent xenograft model by inhibiting cell migration and invasion [54]. Other interesting flavonoids are naringenin, obtained from citrus peel, which has been shown to inhibit proliferation and to induce apoptosis in prostate cancer cells [55], and procyanidin-B2-3,3″-di-O-gallate (B2G2) extracted from grape seeds, that targets both differentiated cells and CSCs leading to tumor mass reduction [56].
Curcumin is another bioactive food product that has been the subject of former numerous studies. Its anti-cancer effects, due its ability to modulate critical anti-apoptotic effectors such as Bcl-xl and NF-κB, are of prominent interest in potential relapse prevention treatments. Moreover, curcumin synergizes with vesicular stomatitis virus (VSV)-based oncolytic treatments modulating antiviral responses and components of the intrinsic apoptotic pathway in a prostate cancer cell model [57]. Furthermore, in colorectal cancer, curcumin can modulate gene expression of HSPA5, SEC61B, G6PD, HMOX1, and PDE3B, affecting essential pathways like DNA replication or the cell cycle. On the other hand, the synergy of curcumin and oligomeric proanthocyanidins emerges as an opportunity to develop effective therapies, since both compounds share similar molecular mechanisms [58]. Recently, relevant effects of curcumin in breast cancer cell models have been discovered, being that this compound is able to increase the expression of E-cadherin and decrease the expression of mesenchymal markers [59]. It has been also shown that curcumin enhances the effect of some targeted drugs used in cancer such as gefitinib, an EGFR inhibitor, inducing autophagy-mediated apoptosis. This observation opens up opportunities for the use of this compound with treatments to prevent cancer relapse [60].
Some lipid character food bioactives also show anti-cancer effects with mechanisms of action interesting for cancer relapse prevention. In this sense, docosahexaenoic acid (DHA) modulates the growth of colorectal cancer cells and induces expression of genes related to apoptosis [61][62]. Also, β-sitosterol-d-glucoside has inhibitory effects on breast cancer cells growth [63].
The studies mentioned above explain many of the effects on cell growth, tumor progression and metastasis of food bioactive products, opening promising opportunities for the application of these phytochemical foodstuffs in therapies for cancer relapse in breast, prostate, lung, and colon cancer. However, no studies of individual food products were found that applied to leukemia relapse. Regarding this type of cancer, only one paper was recovered, suggesting that additional research should be made in this sense. The cited article analyses the effects of a ginger extract rich in gingerols, demonstrating that this extract exerts a synergistic interaction with methotrexate with high antiproliferative impact in the drug-resistant leukemic sub-lines [64]. Nevertheless, the mechanism that supports this effect is not explained. Indeed, the same happens with other food extracts recently studied and would require additional studies.
In general, interesting antitumoral, antiproliferative, or antimetastatic effects are demonstrated, however, the molecular mechanisms concerning these effects remain largely unknown in most cases. An exception may be the grape seed extract, rich in proanthocyanidins associated with antitumor effects in colorectal cancer in combination with curcumin, by regulating cell cycle and migration [65]. Other extracts with identified effects on cell growth, tumor progression and metastasis in colorectal cancer are watercress extract, rich in phenethyl isothiocyanate [66]; ginseng extract, rich in ginsenoside Rg3 [67]; and isodon extract, rich in flexicaulin A [68]. Importantly, orange peel extract, rich in nobiletin, sinensetin, scutellarein tetramethylether, and tangeretin, exerts a synergistic interaction with 5-fluorouracil in colorectal cancer, modulating EMT transition, inhibiting cell proliferation and modulating cancer stemness, demonstrating a significant potential use of this combination in relapse preventive therapies [69]. In any case, further research needs to be done in order to identify molecular mechanisms regarding the effects of these extracts. Although only individual compounds are now useful in precision nutritional strategies against well-identified therapeutic targets, these studies allow considering the extracts as an intermediate step towards the purification of the specific component responsible for the observed effect. In addition, the low toxicity of these extracts makes them suitable for other support therapies as nutritional supplements.
One of the barriers to be overcome in the application of bioactive phytochemical foodstuffs in cancer therapies is the frequent lack of bioavailability of these products. In this sense, new formulation strategies are being developed, such as bioactive carrier lipids in which the carrier not only increases bioavailability, but also provides a synergistic biological activity with the active ingredient. Interestingly, it has been reported that the use of shark liver oil rich in alkylglycerols as a bioactive lipid vehicle for rosemary extract shows synergistic effects in the expression of genes associated with immune modulation, inflammation, oxidative stress, lipid metabolism, and tumorigenesis in colorectal cancer [70]. Besides this, a good example of a non-soluble and instable product is curcumin. This compound is emerging as a potent effector acting on numerous signaling and molecular pathways that regulate tumor growth and cancer relapse. Despite the growing knowledge about its properties, curcumin cannot be approved as a therapeutic compound due to its limitations in terms of bioavailability and stability. Regarding this, several formulation studies are being performed and a significant number of cases have provided better therapeutic results than the individual bioactive [71][72][73][74][75].

3. Conclusions

Although, in the context of cancer research, studies that refer to nutritional therapies based on the use of bioactive foodstuffs in adjuvant treatments are still limited, current results are encouraging since there are several phytochemical bioactive foodstuffs with proven modulating effects of tumor growth, progression, and metastasis, and therefore can be tested in humans with a reasonable probability of success if they are applied in cancer relapse treatments (Figure 1). In this sense, the compounds currently identified for this purpose are in general extensively-studied products in the last years such as the polyphenols apigenin, epigallocatechin gallate, procyanidin B2-3,3-di-O-gallate, quercetin, naringenin, secoisolariciresinol diglucoside, and curcumin, as well as docosahexaenoic acid and β-Sitosterol-d-glucoside lipids. Among the targeted cancers included in this work, lung and colon cancer are being widely studied, and prostate and breast cancer have concentrated the largest number of applications. However, there is a great lack of studies related to the use of phytochemical foodstuffs in leukemia therapies and more studies are needed in this disease. The possibilities of using foodstuffs in cancer treatments and more specifically anti-relapse therapies, are being reinforced with the development of formulation technologies that significantly increase the efficiency of these products.
/media/item_content/202110/6178a27ac2b9bnutrients-11-02799-g002.png
Figure 1. Bioactive foodstuffs and natural extracts with proven effects in cancer treatment. (created with BioRender).
Cancer heterogeneity is one of the features of this disease that makes its treatment particularly challenging. Innovative therapies for patients are continuously being tested and progress has been made in the last years developing early diagnosis protocols and improving patient prognosis. However, despite these efforts, a high percentage of patients relapse after surgery or initial therapy. Cancer relapse involves a great number of different molecular mechanisms that vary form one patient to another. This points to precision medicine as a key element to personalize cancer treatment and prevent relapse, and suggest the value of new effective and safe compounds that potentiate the effects of already-known chemotherapy agents. In this sense, the growing number of studies regarding the mechanisms of several bioactive foodstuffs in the treatment of different types of cancer, open a new layer in precision cancer therapy. Its association with specific genetic targets or different molecular pathways inhibiting tumor growth and metastasis constitutes an important customization component. Moreover, it shows high synergism with several chemotherapy drugs, acting as enhancers of these anti-tumor effects or even sensitizing and reverting chemotherapy resistance. In essence, these products are emerging as novel complementary agents that can be useful in precision nutrition therapies addressing relapse prevention in treatments of cancerous processes.

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018, 68, 394–424.
  2. Chen, Y.; Zhang, Y.; Wang, J.; Chen, N.; Fang, W.; Zhong, J.; Liu, Y.; Qin, R.; Yu, X.; Sun, Z.; et al. A 17 gene panel for non-small-cell lung cancer prognosis identified through integrative epigenomic-transcriptomic analyses of hypoxia-induced epithelial–mesenchymal transition. Mol. Oncol. 2019, 13, 1490–1502.
  3. Wu, Z.; Qiu, M.; Mi, Z.; Meng, M.; Guo, Y.; Jiang, X.; Fang, J.; Wang, H.; Zhao, J.; Liu, Z.; et al. WT1-interacting protein inhibits cell proliferation and tumorigenicity in non-small-cell lung cancer via the AKT/FOXO1 axis. Mol. Oncol. 2019, 13, 1059–1074.
  4. Choi, H.; Deng, J.; Li, S.; Silk, T.; Dong, L.; Brea, E.J.; Houghton, S.; Redmond, D.; Zhong, H.; Boiarsky, J.; et al. Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Rep. 2019, 27, 806–819.
  5. Hamdan, D.; Nguyen, T.T.; Leboeuf, C.; Meles, S.; Janin, A.; Bousquet, G. Genomics applied to the treatment of breast cancer. Oncotarget 2019, 10, 4786–4801.
  6. Bouchal, P.; Schubert, O.T.; Faktor, J.; Capkova, L.; Imrichova, H.; Zoufalova, K.; Paralova, V.; Hrstka, R.; Liu, Y.; Ebhardt, H.A.; et al. Breast Cancer Classification Based on Proteotypes Obtained by SWATH Mass Spectrometry. Cell Rep. 2019, 28, 832–843.
  7. Kido, T.; Li, Y.; Tanaka, Y.; Dahiya, R.; Lau, Y.-F.C. The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner. Oncotarget 2019, 10, 1491–1506.
  8. Wang, D.; Wan, X.; Zhang, Y.; Kong, Z.; Lu, Y.; Sun, X.; Huang, Y.; Ji, C.; Li, D.; Luo, J.; et al. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate 2019, 79, 1379–1393.
  9. Kumar, P.; Chakraborty, J.; Sukumar, G.; Dalgard, C.; Chatterjee, R.; Biswas, R. Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer. Oncotarget 2019, 10, 4290–4306.
  10. Cruz-Gil, S.; Sanchez-Martinez, R.; Gomez de Cedron, M.; Martin-Hernandez, R.; Vargas, T.; Molina, S.; Herranz, J.; Davalos, A.; Reglero, G.; Ramirez de Molina, A. Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role. J. Lipid Res. 2018, 59, 14–24.
  11. Ohata, H.; Shiokawa, D.; Obata, Y.; Sato, A.; Sakai, H.; Fukami, M.; Hara, W.; Taniguchi, H.; Ono, M.; Nakagama, H.; et al. NOX1-Dependent mTORC1 Activation via S100A9 Oxidation in Cancer Stem-like Cells Leads to Colon Cancer Progression. Cell Rep. 2019, 28, 1282–1295.
  12. Vargas, T.; Moreno-Rubio, J.; Herranz, J.; Cejas, P.; Molina, S.; Mendiola, M.; Burgos, E.; Custodio, A.B.; De Miguel, M.; Martín-Hernández, R.; et al. 3’UTR Polymorphism in ACSL1 Gene Correlates with Expression Levels and Poor Clinical Outcome in Colon Cancer Patients. PLoS ONE 2016, 11, e0168423.
  13. Zhang, W.; Xiao, J.; Lu, X.; Liu, T.; Jin, X.; Xiao, Y.; He, X. PVT1 (rs13281615) and miR-146a (rs2910164) polymorphisms affect the prognosis of colon cancer by regulating COX2 expression and cell apoptosis: ZHANG et al. J. Cell Physiol. 2019, 234, 17538–17548.
  14. Garrett, W.S. The gut microbiota and colon cancer. Science 2019, 364, 1133–1135.
  15. Ferrando, A.A.; López-Otín, C. Clonal evolution in leukemia. Nat. Med. 2017, 23, 1135–1145.
  16. Speedy, H.E.; Beekman, R.; Chapaprieta, V.; Orlando, G.; Law, P.J.; Martín-García, D.; Gutiérrez-Abril, J.; Catovsky, D.; Beà, S.; Clot, G.; et al. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nat. Commun. 2019, 10, 3615.
  17. Hutmacher, C.; Volta, L.; Rinaldi, F.; Murer, P.; Myburgh, R.; Manz, M.G.; Neri, D. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia. Leuk. Res. 2019, 84, 106178.
  18. Galletti, G.; Scielzo, C.; Barbaglio, F.; Rodriguez, T.V.; Riba, M.; Lazarevic, D.; Cittaro, D.; Simonetti, G.; Ranghetti, P.; Scarfò, L.; et al. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. Cell Rep. 2016, 14, 1748–1760.
  19. Blundon, M.A.; Dasgupta, S. Metabolic Dysregulation Controls Endocrine Therapy–Resistant Cancer Recurrence and Metastasis. Endocrinology 2019, 160, 1811–1820.
  20. Drouillard, A.; Bouvier, A.-M.; Boussari, O.; Romain, G.; Manfredi, S.; Lepage, C.; Faivre, J.; Jooste, V. Net survival in recurrence-free colon cancer patients. Cancer Epidemiol. 2019, 61, 124–128.
  21. Ferguson, L.R.; De Caterina, R.; Görman, U.; Allayee, H.; Kohlmeier, M.; Prasad, C.; Choi, M.S.; Curi, R.; de Luis, D.A.; Gil, Á.; et al. Guide and Position of the International Society of Nutrigenetics/Nutrigenomics on Personalised Nutrition: Part 1—Fields of Precision Nutrition. J. Nutrigenet. Nutrigenom. 2016, 9, 12–27.
  22. Zeisel, S.H. A Conceptual Framework for Studying and Investing in Precision Nutrition. Front. Genet. 2019, 10, 200.
  23. Mills, S.; Stanton, C.; Lane, J.A.; Smith, G.J.; Ross, R.P. Precision Nutrition and the Microbiome, Part I: Current State of the Science. Nutrients 2019, 11, 923.
  24. Martín-Hernández, R.; Reglero, G.; Dávalos, A. Data mining of nutrigenomics experiments: Identification of a cancer protective gene signature. J. Funct. Foods 2018, 42, 380–386.
  25. Wanchai, A.; Armer, J.M.; Stewart, B.R. Complementary and Alternative Medicine Use among Women with Breast Cancer: A Systematic Review. Clin. J. Oncol. Nurs. 2010, 14, E45–E55.
  26. Lopes, C.M.; Dourado, A.; Oliveira, R. Phytotherapy and Nutritional Supplements on Breast Cancer. BioMed Res. Int. 2017, 2017, 1–42.
  27. Hauner, H.; Weigl, J.; Hauner, D. Can Nutrition Lower the Risk of Recurrence in Breast Cancer? Breast Care 2018, 13, 86–91.
  28. Younas, M.; Hano, C.; Giglioli-Guivarc’h, N.; Abbasi, B.H. Mechanistic evaluation of phytochemicals in breast cancer remedy: Current understanding and future perspectives. RSC Adv. 2018, 8, 29714–29744.
  29. De Cicco, P.; Catani, M.V.; Gasperi, V.; Sibilano, M.; Quaglietta, M.; Savini, I. Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence. Nutrients 2019, 11, 1514.
  30. Sayeed, M.d.A.; Bracci, M.; Lazzarini, R.; Tomasetti, M.; Amati, M.; Lucarini, G.; Di Primio, R.; Santarelli, L. Use of potential dietary phytochemicals to target miRNA: Promising option for breast cancer prevention and treatment? J. Funct. Foods 2017, 28, 177–193.
  31. Ferguson, L.R.; Chen, H.; Collins, A.R.; Connell, M.; Damia, G.; Dasgupta, S.; Malhotra, M.; Meeker, A.K.; Amedei, A.; Amin, A.; et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin. Cancer Biol. 2015, 35, S5–S24.
  32. Braakhuis, A.; Campion, P.; Bishop, K. Reducing Breast Cancer Recurrence: The Role of Dietary Polyphenolics. Nutrients 2016, 8, 547.
  33. Zamora-Ros, R.; Barupal, D.K.; Rothwell, J.A.; Jenab, M.; Fedirko, V.; Romieu, I.; Aleksandrova, K.; Overvad, K.; Kyrø, C.; Tjønneland, A.; et al. Dietary flavonoid intake and colorectal cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort. Int. J. Cancer 2017, 140, 1836–1844.
  34. Ziaei, S.; Halaby, R. Dietary Isoflavones and Breast Cancer Risk. Medicines 2017, 4, 18.
  35. Iqbal, J.; Abbasi, B.A.; Ahmad, R.; Mahmood, T.; Kanwal, S.; Ali, B.; Khalil, A.T.; Shah, S.A.; Alam, M.M.; Badshah, H. Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications. Biomed. Pharmacother. 2018, 108, 752–756.
  36. Jaman, M.d.S.; Sayeed, M.d.A. Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: Current evidence and future perspectives. Breast Cancer 2018, 25, 517–528.
  37. Gianfredi, V.; Nucci, D.; Abalsamo, A.; Acito, M.; Villarini, M.; Moretti, M.; Realdon, S. Green Tea Consumption and Risk of Breast Cancer and Recurrence—A Systematic Review and Meta-Analysis of Observational Studies. Nutrients 2018, 10, 1886.
  38. Darband, S.G.; Kaviani, M.; Yousefi, B.; Sadighparvar, S.; Pakdel, F.G.; Attari, J.A.; Mohebbi, I.; Naderi, S.; Majidinia, M. Quercetin: A functional dietary flavonoid with potential chemo-preventive properties in colorectal cancer. J. Cell Physiol. 2018, 233, 6544–6560.
  39. Paller, C.J.; Pantuck, A.; Carducci, M.A. A review of pomegranate in prostate cancer. Prostate Cancer Prostatic Dis. 2017, 20, 265–270.
  40. Paller, C.J.; Zhou, X.C.; Heath, E.I.; Taplin, M.-E.; Mayer, T.; Stein, M.N.; Bubley, G.J.; Pili, R.; Hudson, T.; Kakarla, R.; et al. Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clin. Cancer Res. 2018, 24, 306–315.
  41. Gómez de Cedrón, M.; Vargas, T.; Madrona, A.; Jiménez, A.; Pérez-Pérez, M.-J.; Quintela, J.-C.; Reglero, G.; San-Félix, A.; Ramírez de Molina, A. Novel Polyphenols That Inhibit Colon Cancer Cell Growth Affecting Cancer Cell Metabolism. J. Pharmacol. Exp. Ther. 2018, 366, 377–389.
  42. Kouhpeikar, H.; Butler, A.E.; Bamian, F.; Barreto, G.E.; Majeed, M.; Sahebkar, A. Curcumin as a therapeutic agent in leukemia. J. Cell Physiol. 2019, 234, 12404–12414.
  43. González-Vallinas, M.; Reglero, G.; Ramírez de Molina, A. Rosemary (Rosmarinus officinalis L.) Extract as a Potential Complementary Agent in Anticancer Therapy. Nutr. Cancer 2015, 67, 1223–1231.
  44. Aguirre-Portolés, C.; Fernández, L.; Ramírez de Molina, A. Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer. Nutrients 2017, 9, 1076.
  45. Carayol, M.; Ninot, G.; Senesse, P.; Bleuse, J.-P.; Gourgou, S.; Sancho-Garnier, H.; Sari, C.; Romieu, I.; Romieu, G.; Jacot, W. Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: The “APAD1” randomized controlled trial. BMC Cancer 2019, 19, 737.
  46. Maruca, A.; Catalano, R.; Bagetta, D.; Mesiti, F.; Ambrosio, F.A.; Romeo, I.; Moraca, F.; Rocca, R.; Ortuso, F.; Artese, A.; et al. The Mediterranean Diet as source of bioactive compounds with multi-targeting anti-cancer profile. Eur. J. Med. Chem. 2019, 181, 111579.
  47. La, X.; Zhang, L.; Li, Z.; Li, H.; Yang, Y. (−)-Epigallocatechin Gallate (EGCG) Enhances the Sensitivity of Colorectal Cancer Cells to 5-FU by Inhibiting GRP78/NF-κB/miR-155-5p/MDR1 Pathway. J. Agric. Food Chem. 2019, 67, 2510–2518.
  48. Oya, Y.; Mondal, A.; Rawangkan, A.; Umsumarng, S.; Iida, K.; Watanabe, T.; Kanno, M.; Suzuki, K.; Li, Z.; Kagechika, H.; et al. Down-regulation of histone deacetylase 4, −5 and −6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin. J. Nutr. Biochem. 2017, 42, 7–16.
  49. Jiang, P.; Xu, C.; Chen, L.; Chen, A.; Wu, X.; Zhou, M.; Haq, I.U.; Mariyam, Z.; Feng, Q. Epigallocatechin-3-gallate inhibited cancer stem cell-like properties by targeting hsa-mir-485-5p/RXRα in lung cancer. J. Cell. Biochem. 2018, 119, 8623–8635.
  50. Song, X.; Zhang, M.; Chen, L.; Lin, Q. Bioinformatic Prediction of Possible Targets and Mechanisms of Action of the Green Tea Compound Epigallocatechin-3-Gallate Against Breast Cancer. Front. Mol. Biosci. 2017, 4, 43.
  51. Erdogan, S.; Turkekul, K.; Dibirdik, I.; Doganlar, O.; Doganlar, Z.B.; Bilir, A.; Oktem, G. Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway. Biomed. Pharmacother. 2018, 107, 793–805.
  52. Li, X.; Zhou, N.; Wang, J.; Liu, Z.; Wang, X.; Zhang, Q.; Liu, Q.; Gao, L.; Wang, R. Quercetin suppresses breast cancer stem cells (CD44 + /CD24 − ) by inhibiting the PI3K/Akt/mTOR-signaling pathway. Life Sci. 2018, 196, 56–62.
  53. Erdogan, S.; Turkekul, K.; Serttas, R.; Erdogan, Z. The natural flavonoid apigenin sensitizes human CD44 + prostate cancer stem cells to cisplatin therapy. Biomed. Pharmacother. 2017, 88, 210–217.
  54. Chang, J.-H.; Cheng, C.-W.; Yang, Y.-C.; Chen, W.-S.; Hung, W.-Y.; Chow, J.-M.; Chen, P.-S.; Hsiao, M.; Lee, W.-J.; Chien, M.-H. Downregulating CD26/DPPIV by apigenin modulates the interplay between Akt and Snail/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses. J. Exp. Clin. Cancer Res. 2018, 37, 199.
  55. Lim, W.; Park, S.; Bazer, F.W.; Song, G. Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways: Effects of Naringenin on Prostate Cancer Cells. J. Cell. Biochem. 2017, 118, 1118–1131.
  56. Tyagi, A.; Kumar, S.; Raina, K.; Wempe, M.F.; Maroni, P.D.; Agarwal, R.; Agarwal, C. Differential effect of grape seed extract and its active constituent procyanidin B2 3,3″-di-O-gallate against prostate cancer stem cells. Mol. Carcinog. 2019, 58, 1105–1117.
  57. Fehl, D.J.; Ahmed, M. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers. Virus Res. 2017, 228, 14–23.
  58. Ravindranathan, P.; Pasham, D.; Balaji, U.; Cardenas, J.; Gu, J.; Toden, S.; Goel, A. A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer. Sci. Rep. 2018, 8, 13869.
  59. Hu, C.; Li, M.; Guo, T.; Wang, S.; Huang, W.; Yang, K.; Liao, Z.; Wang, J.; Zhang, F.; Wang, H. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT. Phytomedicine 2019, 58, 152740.
  60. Chen, P.; Huang, H.-P.; Wang, Y.; Jin, J.; Long, W.-G.; Chen, K.; Zhao, X.-H.; Chen, C.-G.; Li, J. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. J. Exp. Clin. Cancer Res. 2019, 38, 254.
  61. Ortea, I.; González-Fernández, M.J.; Ramos-Bueno, R.P.; Guil-Guerrero, J.L. Proteomics Study Reveals That Docosahexaenoic and Arachidonic Acids Exert Different In Vitro Anticancer Activities in Colorectal Cancer Cells. J. Agric. Food Chem. 2018, 66, 6003–6012.
  62. Dumont, A.; de Rosny, C.; Kieu, T.-L.-V.; Perrey, S.; Berger, H.; Fluckiger, A.; Muller, T.; Pais de Barros, J.-P.; Pichon, L.; Hichami, A.; et al. Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: Implication in cancer treatment. Cell Death Dis. 2019, 10, 485.
  63. Xu, H.; Li, Y.; Han, B.; Li, Z.; Wang, B.; Jiang, P.; Zhang, J.; Ma, W.; Zhou, D.; Li, X.; et al. Anti-breast-Cancer Activity Exerted by β-Sitosterol- d -glucoside from Sweet Potato via Upregulation of MicroRNA-10a and via the PI3K–Akt Signaling Pathway. J. Agric. Food Chem. 2018, 66, 9704–9718.
  64. Rahimi Babasheikhali, S.; Rahgozar, S.; Mohammadi, M. Ginger extract has anti-leukemia and anti-drug resistant effects on malignant cells. J. Cancer Res. Clin. Oncol. 2019, 145, 1987–1998.
  65. Ravindranathan, P.; Pasham, D.; Balaji, U.; Cardenas, J.; Gu, J.; Toden, S.; Goel, A. Mechanistic insights into anticancer properties of oligomeric proanthocyanidins from grape seeds in colorectal cancer. Carcinogenesis 2018, 39, 767–777.
  66. Pereira, L.; Silva, P.; Duarte, M.; Rodrigues, L.; Duarte, C.; Albuquerque, C.; Serra, A. Targeting Colorectal Cancer Proliferation, Stemness and Metastatic Potential Using Brassicaceae Extracts Enriched in Isothiocyanates: A 3D Cell Model-Based Study. Nutrients 2017, 9, 368.
  67. Liu, T.; Duo, L.; Duan, P. Ginsenoside Rg3 Sensitizes Colorectal Cancer to Radiotherapy through Downregulation of Proliferative and Angiogenic Biomarkers. Evid. Based Complement. Altern. Med. 2018, 2018, 1–8.
  68. Xia, Y.; Lam, C.S.; Li, W.; Sarwar, M.d.S.; Liu, K.; Lee, K.M.; Zhang, H.-J.; Tsang, S.W. Flexicaulin A, An ent-Kaurane Diterpenoid, Activates p21 and Inhibits the Proliferation of Colorectal Carcinoma Cells through a Non-Apoptotic Mechanism. IJMS 2019, 20, 1917.
  69. Pereira, C.; Duarte, M.; Silva, P.; Bento da Silva, A.; Duarte, C.; Cifuentes, A.; García-Cañas, V.; Bronze, M.; Albuquerque, C.; Serra, A. Polymethoxylated Flavones Target Cancer Stemness and Improve the Antiproliferative Effect of 5-Fluorouracil in a 3D Cell Model of Colorectal Cancer. Nutrients 2019, 11, 326.
  70. Gómez de Cedrón, M.; Laparra, J.M.; Loria-Kohen, V.; Molina, S.; Moreno-Rubio, J.; Montoya, J.J.; Torres, C.; Casado, E.; Reglero, G.; Ramírez de Molina, A. Tolerability and Safety of a Nutritional Supplement with Potential as Adjuvant in Colorectal Cancer Therapy: A Randomized Trial in Healthy Volunteers. Nutrients 2019, 11, 2001.
  71. Pandolfi, L.; Bellini, M.; Vanna, R.; Morasso, C.; Zago, A.; Carcano, S.; Avvakumova, S.; Bertolini, J.A.; Rizzuto, M.A.; Colombo, M.; et al. H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells. Biomacromolecules 2017, 18, 3318–3330.
  72. Greish, K.; Pittalà, V.; Taurin, S.; Taha, S.; Bahman, F.; Mathur, A.; Jasim, A.; Mohammed, F.; El-Deeb, I.; Fredericks, S.; et al. Curcumin–Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer. Nanomaterials 2018, 8, 884.
  73. Bessone, F.; Argenziano, M.; Grillo, G.; Ferrara, B.; Pizzimenti, S.; Barrera, G.; Cravotto, G.; Guiot, C.; Stura, I.; Cavalli, R.; et al. Low-dose curcuminoid-loaded in dextran nanobubbles can prevent metastatic spreading in prostate cancer cells. Nanotechnology 2019, 30, 214004.
  74. Yang, Z.; Sun, N.; Cheng, R.; Zhao, C.; Liu, J.; Tian, Z. Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. J. Mater. Chem. B 2017, 5, 6762–6775.
  75. Yang, Z.; Sun, N.; Cheng, R.; Zhao, C.; Liu, Z.; Li, X.; Liu, J.; Tian, Z. pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. Biomaterials 2017, 147, 53–67.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Nutrition & Dietetics
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Guillermo Reglero
View Times: 493
Revisions: 2 times (View History)
Update Date: 27 Oct 2021
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback